Americafirst Capital Management LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,565 shares of the biopharmaceutical company’s stock, valued at approximately $700,000. Regeneron Pharmaceuticals makes up about 0.9% of Americafirst Capital Management LLC’s investment portfolio, making the stock its 21st largest position.

Other large investors have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $217,000. IFM Investors Pty Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $979,000. Fieldpoint Private Securities LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 285.3% during the 3rd quarter. Fieldpoint Private Securities LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 756 shares during the period. Griffin Asset Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $1,579,000. Finally, Piedmont Investment Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 18.4% during the 3rd quarter. Piedmont Investment Advisors LLC now owns 19,811 shares of the biopharmaceutical company’s stock worth $8,858,000 after acquiring an additional 3,076 shares during the period. Institutional investors own 66.67% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $386.67 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals, Inc. has a 1 year low of $340.09 and a 1 year high of $543.55. The stock has a market cap of $41,540.00, a P/E ratio of 33.01, a price-to-earnings-growth ratio of 1.50 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter last year, the company earned $3.13 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% on a year-over-year basis. equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is owned by company insiders.

REGN has been the topic of several recent analyst reports. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $605.00 price objective on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 23rd. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Raymond James Financial reiterated an “outperform” rating and set a $566.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 6th. Finally, Citigroup reiterated a “buy” rating and set a $575.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Two analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $465.22.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/americafirst-capital-management-llc-buys-shares-of-1565-regeneron-pharmaceuticals-inc-regn/1762941.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.